Based on the previous analysis and our funding availability, we acquired and submitted four hits (Figure 4) to experimental testing: the antibiotic methacycline, the antihypertensives benzthiazide and bendroflumethiazide, and the abandoned drug odanacatib (an inhibitor of the cysteine protease cathepsin K that was pursued as a treatment for osteoporosis and bone metastasis but whose development was abandoned at Phase III long-term clinical trials due to safety issues; Drake et al., 2017). The gene discussed is CTSK; the disease is osteoporosis.